264 related articles for article (PubMed ID: 18000804)
1. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
[TBL] [Abstract][Full Text] [Related]
2. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Bahri S; Chen JH; Mehta RS; Carpenter PM; Nie K; Kwon SY; Yu HJ; Nalcioglu O; Su MY
Ann Surg Oncol; 2009 Jun; 16(6):1619-28. PubMed ID: 19333654
[TBL] [Abstract][Full Text] [Related]
3. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.
Kuzucan A; Chen JH; Bahri S; Mehta RS; Carpenter PM; Fwu PT; Yu HJ; Hsiang DJ; Lane KT; Butler JA; Feig SA; Su MY
Clin Breast Cancer; 2012 Apr; 12(2):110-8. PubMed ID: 22444717
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
[TBL] [Abstract][Full Text] [Related]
8. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
[TBL] [Abstract][Full Text] [Related]
9. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
[TBL] [Abstract][Full Text] [Related]
11. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
13. Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery.
Iwase M; Sawaki M; Hattori M; Yoshimura A; Ishiguro J; Kotani H; Gondo N; Adachi Y; Kataoka A; Onishi S; Sugino K; Iwata H
Breast Cancer; 2018 Sep; 25(5):583-589. PubMed ID: 29619758
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
17. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
Londero V; Bazzocchi M; Del Frate C; Puglisi F; Di Loreto C; Francescutti G; Zuiani C
Eur Radiol; 2004 Aug; 14(8):1371-9. PubMed ID: 14986052
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
